Why PolarityTE Shares Are Trading Higher On Monday

PolarityTE PTE shares are trading higher after the company announced its Diabetic Foot Ulcers trial met its primary and secondary endpoints.

In the company's multi-center randomized controlled trial, 70% of patients treated with SkinTE plus standard of care showed wound closure at 12 weeks, compared with 34% of patients receiving standard of care alone. Additionally, the SkinTE plus standard of care group showed a percent area reduction of 84.4% compared with 53.5% in the standard of care alone group. 

PolarityTE Inc is a commercial-stage biotechnology and regenerative biomaterials company.

At the time of publication, shares of PolarityTE were trading 24.2% higher at $1.21. The stock has a 52-week low of $0.55 and a 52-week high of $2.38.